117 related articles for article (PubMed ID: 6692433)
1. Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports.
DeVita VT
Cancer Treat Rep; 1984 Jan; 68(1):339-40. PubMed ID: 6692433
[No Abstract] [Full Text] [Related]
2. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435
[No Abstract] [Full Text] [Related]
3. Origins and development of chemotherapy research at the National Cancer Institute.
Zubrod CG
Cancer Treat Rep; 1984 Jan; 68(1):9-19. PubMed ID: 6362871
[No Abstract] [Full Text] [Related]
4. Clinical development of anticancer agents--a National Cancer Institute perspective.
Marsoni S; Wittes R
Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
[No Abstract] [Full Text] [Related]
5. A review of the report of the 1966 Cancer Chemotherapy Collaborative Program Review Committee.
Richardson AP
Cancer Treat Rep; 1984 Jan; 68(1):340-1. PubMed ID: 6692434
[No Abstract] [Full Text] [Related]
6. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
7. Cancer problems lead list for potential medical marijuana research studies.
Smigel K
J Natl Cancer Inst; 1997 Sep; 89(17):1255. PubMed ID: 9293912
[No Abstract] [Full Text] [Related]
8. The National Cancer Institute's Drug Development Program.
Schepartz SA
Prog Clin Biol Res; 1985; 197():73-82. PubMed ID: 4070301
[No Abstract] [Full Text] [Related]
9. Planning combined therapy--the interaction of experimental and clinical studies.
Carter SK
Cancer Chemother Rep 2; 1974 Mar; 4(1):3-11. PubMed ID: 4826498
[No Abstract] [Full Text] [Related]
10. Collection and presentation of combination data.
Mancher RR
Cancer Chemother Rep 2; 1974 Mar; 4(1):167-80. PubMed ID: 4826496
[No Abstract] [Full Text] [Related]
11. An open letter to cancer researchers.
Elledge SJ; Hannon GJ
Science; 2005 Oct; 310(5747):439-41. PubMed ID: 16239460
[No Abstract] [Full Text] [Related]
12. [Present strategy for new drug development in the USA].
Shimada Y
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():315-24. PubMed ID: 7986110
[TBL] [Abstract][Full Text] [Related]
13. Scientists mine for genetic sources of cancer.
Vickery K
Provider; 2004 Feb; 30(2):20-3, 27-8, 33. PubMed ID: 14964916
[No Abstract] [Full Text] [Related]
14. [Past and current problems in tumor research].
von Wasielewski E; Sedlacek HH
Dtsch Med Wochenschr; 1986 Apr; 111(16):630-7. PubMed ID: 3956405
[No Abstract] [Full Text] [Related]
15. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
16. Some thoughts on the reporting of adverse events in phase II cancer clinical trials.
Anderson SJ
J Clin Oncol; 2006 Aug; 24(24):3821-2. PubMed ID: 16921032
[No Abstract] [Full Text] [Related]
17. Open freezer at NCI.
Science; 1992 Jan; 255(5040):27. PubMed ID: 1553526
[No Abstract] [Full Text] [Related]
18. The NCI Developmental Therapeutics Program.
Collins JM
Clin Adv Hematol Oncol; 2006 Apr; 4(4):271-3. PubMed ID: 16728938
[No Abstract] [Full Text] [Related]
19. Adjuvant chemotherapy of breast cancer. Sponsored by the National Cancer Institute, assisted by the Office for Medical Applications of Research, NIH.
Conn Med; 1980 Nov; 44(11):721-3. PubMed ID: 7226778
[No Abstract] [Full Text] [Related]
20. The preclinical new drug research program of the National Cancer Institute.
Driscoll JS
Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
